Quarterly ResultMay 18, 2026, 06:08 AM
OS Therapies Q1 Net Loss $(10.4)M; Going Concern Doubt Raised
AI Summary
OS Therapies Inc. reported a net loss of $(10.4) million for the three months ended March 31, 2026, a significant increase from $(3.9) million in the prior year, with basic and diluted loss per share rising to $(0.27). The company used $(4.6) million in cash for operating activities and held $917,552 in cash as of March 31, 2026. Management has raised substantial doubt about the company's ability to continue as a going concern, citing insufficient cash to fund expected Q2-Q4 2026 expenses of approximately $20.0 million, and is actively seeking additional capital.
Key Highlights
- Net loss for Q1 2026 was $(10.4) million, up from $(3.9) million in Q1 2025.
- Basic and diluted loss per share increased to $(0.27) in Q1 2026 from $(0.18) in Q1 2025.
- Cash and cash equivalents stood at $917,552 as of March 31, 2026.
- Net cash used in operating activities was $(4.6) million for Q1 2026.
- Research and development expenses surged to $7.4 million in Q1 2026 from $1.3 million in Q1 2025.
- Secured $5.2 million in financing activities, including $3.4 million from warrant exercises and $1.8 million from convertible notes.
- Current liabilities increased to $17.0 million as of March 31, 2026, from $11.8 million at year-end 2025.
- Management raised substantial doubt about the company's ability to continue as a going concern.
Price Impact
More from OSTX